Moderna and Merck Treatment Cuts Melanoma Recurrence or Death Risk by 42%
A treatment combining an experimental shot with immunotherapy reduced the risk of melanoma recurrence or death by 42% in a study of more than 1,100 patients. The treatment still requires U.S. approval.
